The Risk of Esophageal Cancer in Relation to the Treatment and Prevention of Osteoporosis in Women (MK-0217A-352)

19/04/2017
11/04/2024
EU PAS number:
EUPAS17909
Study
Finalised
Study identification

EU PAS number

EUPAS17909

Study ID

19310

Official title and acronym

The Risk of Esophageal Cancer in Relation to the Treatment and Prevention of Osteoporosis in Women (MK-0217A-352)

DARWIN EU® study

No

Study countries

United Kingdom

Study description

This is a 2-phase retrospective database study, using both case-cohort and inception (intention-to-treat) cohort analyses to evaluate any association between oral treatments for osteoporosis and the risk of esophageal cancer in women.

Study status

Finalised
Research institutions and networks

Institutions

Merck Sharp & Dohme LLC
United States
First published:
08/07/2025
Institution Pharmaceutical company

Contact details

Clinical Trials Disclosure Merck Sharp & Dohme Corp.

Primary lead investigator

Study timelines

Date when funding contract was signed

Actual:

Study start date

Actual:

Data analysis start date

Actual:

Date of final study report

Actual:
Sources of funding
Pharmaceutical company and other private sector 

More details on funding

Merck Sharp & Dohme Corp.
Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

EU RMP category 3 (required)